The invention pertains to implantable medical devices for controlled delivery of therapeutic agents. Some devices according to the invention have a titanium reservoir, and a porous titanium oxide based membrane to control the rate of release of the therapeutic agent. The reservoir contains a formulation of the active agent, and means to promote water uptake into the reservoir upon implantation. In some embodiments the means include a gas with a higher solubility in than air water.

The invention relates to a device for treating an individual suffering from cardiac or circulatory arrest or from a stroke, comprising a blood withdrawal device (BE) that is applied to the individual (P), an analysis unit (BA) which is directly or indirectly connected to the blood withdrawal device for detecting a blood analysis result (BAE) providing at least one characteristic of the blood, directly or indirectly connected to a blood return device (BR) that is applied to the individual (P) and is designed to deliver a substance to the individual via the return device (BR).

A lymphangiogenesis inducing device includes: an outer needle including a needle point insertable into a subcutaneous tissue, and a through-hole extending in an axial direction and penetrating the outer needle; and an inner needle inserted into the through-hole. The inner needle includes a cavity portion extending along the axial direction, and a wound imparting structure that is formed in a part of a distal end configured to protrude past the needle point of the outer needle and configured to cause a wound on the subcutaneous tissue. The wound imparting structure includes one or more protrusions protruding outward from the inner needle.

A method of treating diverticulitis while maintaining the bioactivity of the diverticulum. The devices and methods include placing an endoscopic device within a colonic lumen relative to at least one diverticulum and inserting a plurality of particles into the at least one diverticulum. The plurality of particles can include magnetic particles, non-magnetic particles, or both. The plurality of particles can partially or totally occlude the diverticulum preventing unwanted material from entering the diverticulum. Additionally, the plurality of particles can include antimicrobial and therapeutic layers that can treat diverticulitis and prevent or minimize diverticulitis from occurring.

In one aspect, an implant removal device for removal of ruptured silicone breast implants includes a hollow container having a middle portion disposed between a first end and a second end. The device also has a connector port coupled to the second end that is coupled to a suction device during use. The device also includes a nozzle coupled to the first end that is configured for placement against an incision of a patient for removing a ruptured breast implant from the patient. The middle portion of the hollow container defines one or more vent holes extending between an interior and exterior container surface with the one or more vent holes configured to reduce negative pressure within the hollow container when the suction device is activated during the removal process.

Embodiments provide apparatus and methods for delivering solid form medications such as drug cords (DC) to various locations in the body. The DCs may comprise one or more drugs and excipients. One embodiment provides an apparatus for in vivo delivery of DCs comprising a housing including a port, a DC disposed in the housing on a spool or like device and a mechanism for advancing the DCs from the inside the housing to a delivery site (DS) outside the housing. The apparatus can be used to deliver selected lengths of DC corresponding to a dose of drug to treat a medical condition. The DC can be delivered to the DS at regular intervals or responsive to a detected biological event. Embodiments of the invention are particularly useful for delivering medication to treat a selected medical condition over an extended period without requiring a patient to take external medication.

Drug delivery devices, medicaments, and methods are provided for the intraperitoneal treatment of ovarian cancer. An implantable device for drug delivery includes an elongated, flexible device having a housing defining a reservoir that contains a drug in solid or semi-solid form, and configured to be wholly deployed within the peritoneal cavity of a patient and continuously release a therapeutically effective amount of the drug over a period of at least 24 hours. A medicament includes cisplatin for administration into the peritoneal cavity of a patient continuously over a treatment period of at least 24 hours. A method of drug delivery includes implanting within the peritoneal cavity of a patient an elongated, flexible device having a reservoir containing a drug, solubilizing the drug at least in part with peritoneal fluid, and releasing an effective amount of the solubilized drug from the reservoir continuously for a period of at least 24 hours.

A medical device comprising an implantable subcutaneous access port having a septum penetrable by a needle; the septum having a cavity located between an outer wall and an inner wall, the cavity containing a flowable media comprising a plurality of displaceable particles arranged to move in response to the needle being inserted through the outer wall and into the cavity and reposition around the needle.

Vascular treatment devices and methods include a woven structure including a plurality of bulbs that may be self-expanding, a hypotube, for example including interspersed patterns of longitudinally spaced rows of kerfs, and a bonding zone between the woven structure and the hypotube. The woven structure may include patterns of radiopaque filaments measurable under x-ray. Structures may be heat treated to include various shapes at different temperatures. The woven structure may be deployable to implant in a vessel. A catheter may include a hypotube including interspersed patterns of longitudinally spaced rows of kerfs and optionally a balloon. Laser cutting systems may include fluid flow systems.

A treatment system delivers a breathing gas and frozen ice or other particles (FSP) to a bronchus of a lung of a patient in order to induce hypothermia. The breathing gas and the FSP are usually delivered through separate lumens. Clogging of an FSP lumen can be inhibited by heating and/or cooling of the lumen. The temperature of exhaled gases or a body temperature may be measured, and a controller can adjust the duration or rate at which the ice particles are delivered in order to control the patient's core temperature based on the measured temperature.